Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.60 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24740182 | 1.00 | PDK2 (0.60) | PDK2PDK4POLBLMNAGAA | |
| SCHEMBL5497405 | 0.86 | MAPT (0.48) | PDK2PDK4POLBLMNAGAA | |
| SCHEMBL5496567 | 0.84 | PDK2 (0.44) | PDK2PDK4POLBLMNAGAA | |
| SCHEMBL11535997 | 0.84 | PDK2 (0.47) | PDK2PDK4POLBLMNAGAA | |
| SCHEMBL16822019 | 0.80 | PDK2 (0.55) | PDK2PDK4POLBLMNAGAA | |
| SCHEMBL19410666 | 0.80 | PDK2 (0.55) | PDK2PDK4POLBLMNAGAA | |
| SCHEMBL7834463 | 0.80 | PGR (0.59) | PDK2PDK4LMNAATMALDH1A1 | |
| SCHEMBL12747116 | 0.79 | PDK2 (0.53) | PDK2PDK4POLBLMNAGAA | |
| SCHEMBL28513117 | 0.79 | PDK2 (0.53) | PDK2PDK4POLBLMNAGAA | |
| Hydrochloric Acid SCHEMBL16822147 | 0.79 | PDK2 (0.53) | PDK2PDK4POLBLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556070-B1 | SYNTHESIS OF CHIRAL 2-(1H-INDAZOL-6-YL)-SPIRO[CYCLOPROPANE-1,3'- INDOLIN]-2'-ONES | UNIV HEALTH NETWORK (CA) | 2017-06-07 | — | — | EP | disclosed |
| WO-2007075946-A1 | COMPOUNDS USEFUL IN CFTR ASSAYS AND METHODS THEREWITH | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1778222-A1 | PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF | Wyeth (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006023107-A1 | PROGESTERONE RECEPTOR MODULATORS COMPRISING PYRROLE-OXINDOLE DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060030615-A1 | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | WYETH (US) | 2006-02-09 | — | — | US | disclosed |
| EP-0780388-B1 | 5HT1Dalpha and 5HT2A ligands | LILLY CO ELI (GB) | 2001-08-16 | — | — | EP | disclosed |
| US-6166040-A | Indole compounds | ELI LILLY AND COMPANY LIMITED (GB) | 2000-12-26 | — | — | US | disclosed |
| EP-0963983-A1 | Indol-2-ones as serotonin modulators | ELI LILLY AND COMPANY LIMITED (GB) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999058525-A1 | INDOLE DERIVATIVES AS 5-HT2A LIGANDS AND AS SEROTONINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY LIMITED (GB) | 1999-11-18 | — | — | WO | disclosed |
| US-5773448-A | NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY LIMITED (GB) | 1998-06-30 | — | — | US | disclosed |
| EP-0780388-A1 | 5HT1Dalpha and 5HT2A ligands | LILLY INDUSTRIES LIMITED (GB) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030615-A1 | Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof | PGR, PGRMC2, PGRMC1 | PDK2 394/4885PDK4 595/4885POLB 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.